ADAP News and Press, Adaptimmune Therapeutics plc From 08/20/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Adaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Conference Call August 09, 2021, 04:30 PM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Helen Tayton-Martin - Co-Founder and Chief Business Officer Elliot Norry - Senior VP and Chief Medical Officer John Lunger - Chief Pat...

Image source: The Motley Fool. Adaptimmune Therapeutics plc (NASDAQ: ADAP) Q2 2021 Earnings Call Aug 9, 2021 , 4:20 p.m. ET Operator Continue reading For further details see: Adaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Call Trans...

- SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year - - SURPASS trial data from 23 evaluable patients to be presented at ESMO - - ADP-A2AFP Phase 1 trial data from 11 evaluable patient...

Shares have fallen significantly from peak achieved in Q3 2020. It appears that the TCR space could be ready to come of age, and there's room for multiple winners here. I found presentations by management to be refreshing (straightforward, continually improving product profile, focusi...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter ended June 30, 2021, after the US markets ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) traded today at a new 52-week low of $3.55. This new low was reached on below average trading volume as 263,000 shares traded hands, while the average 30-day volume is approximately 797,000 shares. There is potential upside of 1.2% for shares of...

Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) , a small-cap cancer immunotherapy company, slid by a hefty 21% during the first six months of 2021, according to data from S&P Global Market Intelligence . By contrast, the biotech's shares were among the hottest in the enti...

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) traded at a new 52-week low today of $3.63. So far today approximately 263,000 shares have been exchanged, as compared to an average 30-day volume of 799,000 shares. Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical co...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...